metformin has been researched along with pentoxifylline in 15 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 6 (40.00) | 29.6817 |
| 2010's | 7 (46.67) | 24.3611 |
| 2020's | 2 (13.33) | 2.80 |
| Authors | Studies |
|---|---|
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Choi, SS; Contrera, JF; Hastings, KL; Kruhlak, NL; Sancilio, LF; Weaver, JL; Willard, JM | 1 |
| Afshari, CA; Eschenberg, M; Hamadeh, HK; Lee, PH; Lightfoot-Dunn, R; Morgan, RE; Qualls, CW; Ramachandran, B; Trauner, M; van Staden, CJ | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Gonzales, N; Nadler, JL; Natarajan, R; Rahbar, S; Scott, S; Yerneni, K | 1 |
| Abdollahi, M; Hadjibabaie, M; Larijani, B; Mojtahedi, A; Radfar, M; Rajabipour, B | 1 |
| Comar, KM; Sterling, RK | 1 |
| Rapin, JR; Wiernsperger, N | 1 |
| Ganesh, S; Rustgi, VK | 1 |
| Donoviel, DB; Jones, JA; McLaughlin, MF | 1 |
| Atkin, SL; De Vincentis, A; Jamialahmadi, T; Mahjoubin-Tehran, M; Mantzoros, CS; Mikhailidis, DP; Sahebkar, A | 1 |
| da Silva Junior, VA; de Oliveira Filho, EF; de Oliveira, EL; de Oliveira, JS; Dias, FCR; Ferreira, CMO; Silva, AADN; Soares, PC | 1 |
7 review(s) available for metformin and pentoxifylline
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Review article: Drug therapy for non-alcoholic fatty liver disease.
Topics: Angiotensin-Converting Enzyme Inhibitors; Antioxidants; Ascorbic Acid; Betaine; Cholagogues and Choleretics; Enzyme Inhibitors; Fatty Liver; Humans; Hypoglycemic Agents; Lipotropic Agents; Metformin; Pentoxifylline; Probucol; Thiazolidinediones; Ursodeoxycholic Acid; Vitamin E | 2006 |
Microvascular diseases: is a new era coming?
Topics: Diabetic Angiopathies; Hemorheology; Humans; Metformin; Microcirculation; Microvessels; Myocardial Ischemia; Pentoxifylline; Plant Extracts; Vascular Diseases; Vasodilator Agents | 2012 |
Current Pharmacologic Therapy for Nonalcoholic Fatty Liver Disease.
Topics: Angiotensin Receptor Antagonists; Anti-Inflammatory Agents, Non-Steroidal; Anti-Obesity Agents; Anticholesteremic Agents; Antioxidants; Cannabinoid Receptor Antagonists; Cholagogues and Choleretics; Fatty Acids, Omega-3; Glucagon-Like Peptide-1 Receptor; Humans; Hypoglycemic Agents; Insulin Resistance; Lactones; Metformin; Non-alcoholic Fatty Liver Disease; Orlistat; Pentoxifylline; Piperidines; Probiotics; Pyrazoles; Rimonabant; Synbiotics; Thiazolidinediones; Ursodeoxycholic Acid; Vitamin E | 2016 |
Novel Indications for Commonly Used Medications as Radiation Protectants in Spaceflight.
Topics: Acetylcysteine; Adrenergic beta-Antagonists; Aerospace Medicine; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Anti-Inflammatory Agents, Non-Steroidal; Astronauts; Calcium Channel Blockers; Fingolimod Hydrochloride; Free Radical Scavengers; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemic Agents; Immunosuppressive Agents; Metformin; Pentoxifylline; Radiation Injuries; Radiation-Protective Agents; Space Flight | 2017 |
Non-alcoholic fatty liver disease and steatohepatitis: State of the art on effective therapeutics based on the gold standard method for diagnosis.
Topics: Biopsy; Disease Progression; Humans; Liver; Liver Cirrhosis; Metformin; Non-alcoholic Fatty Liver Disease; Pentoxifylline; Pioglitazone; Randomized Controlled Trials as Topic; Rosiglitazone; Severity of Illness Index; Treatment Outcome; Ursodeoxycholic Acid; Vitamin E | 2021 |
Histomorphometric and oxidative evaluation of the offspring's testis from type 2 diabetic female rats treated with metformin and pentoxifylline.
Topics: Animals; Diabetes Mellitus, Type 2; Female; Lipid Peroxidation; Male; Metformin; Oxidative Stress; Pentoxifylline; Pregnancy; Rats; Reactive Oxygen Species; Semen; Spermatogenesis; Testis; Testosterone | 2022 |
1 trial(s) available for metformin and pentoxifylline
| Article | Year |
|---|---|
Effects of pentoxifylline on oxidative stress and levels of EGF and NO in blood of diabetic type-2 patients; a randomized, double-blind placebo-controlled clinical trial.
Topics: Diabetes Mellitus, Type 2; Double-Blind Method; Epidermal Growth Factor; Female; Free Radical Scavengers; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Lipid Peroxidation; Male; Metformin; Middle Aged; Nitric Oxide; Oxidative Stress; Pentoxifylline; Sulfonylurea Compounds; Thiobarbituric Acid Reactive Substances; Time Factors; Treatment Outcome | 2005 |
7 other study(ies) available for metformin and pentoxifylline
| Article | Year |
|---|---|
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Topics: | 2008 |
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Assay; Biological Transport; Cell Line; Cell Membrane; Chemical and Drug Induced Liver Injury; Cytoplasmic Vesicles; Drug Evaluation, Preclinical; Humans; Liver; Rats; Reproducibility of Results; Spodoptera; Transfection; Xenobiotics | 2010 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Evidence that pioglitazone, metformin and pentoxifylline are inhibitors of glycation.
Topics: Enzyme-Linked Immunosorbent Assay; Glycated Hemoglobin; Glycation End Products, Advanced; Humans; Hypoglycemic Agents; Metformin; Pentoxifylline; Pioglitazone; Thiazoles; Thiazolidinediones | 2000 |